EA200800548A1 - HYBRID POLYPEPTIDES WITH SELECTED PROPERTIES - Google Patents

HYBRID POLYPEPTIDES WITH SELECTED PROPERTIES

Info

Publication number
EA200800548A1
EA200800548A1 EA200800548A EA200800548A EA200800548A1 EA 200800548 A1 EA200800548 A1 EA 200800548A1 EA 200800548 A EA200800548 A EA 200800548A EA 200800548 A EA200800548 A EA 200800548A EA 200800548 A1 EA200800548 A1 EA 200800548A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diabetes
type
hybrid polypeptides
disorders
insulin
Prior art date
Application number
EA200800548A
Other languages
Russian (ru)
Other versions
EA014647B1 (en
Inventor
Одиль Эстер Леви
Майкл Р. Ханли
Кэролин М. Джодка
Диана Льюис
Кристофер Дж. Соарес
Соумитра С. Гхош
Лоуренс Д'соуза
Дэвид Г. Паркес
Кристин М. Мэк
Бехроуз Брюс Форуд
Original Assignee
Амилин Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/206,903 external-priority patent/US8076288B2/en
Priority claimed from US11/301,744 external-priority patent/US7723471B2/en
Application filed by Амилин Фармасьютикалз, Инк. filed Critical Амилин Фармасьютикалз, Инк.
Priority claimed from PCT/US2006/031724 external-priority patent/WO2007022123A2/en
Publication of EA200800548A1 publication Critical patent/EA200800548A1/en
Publication of EA014647B1 publication Critical patent/EA014647B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Данное изобретение главным образом относится к новым, селектируемым гибридным полипептидам, пригодным в качестве агентов для лечения и профилактики заболеваний и нарушений обмена веществ, которые могут быть облегчены контролем уровней глюкозы плазмы, уровней инсулина и/или секреции инсулина, таких как диабет и связанные с диабетом состояния. Такие состояния и нарушения включают, но не ограничены ими, гипертонию, дислипидемию, сердечно-сосудистое заболевание, нарушения питания, резистентность к инсулину, ожирение и сахарный диабет любого типа, включая тип 1, тип 2 и диабет при беременности.This invention mainly relates to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of diseases and metabolic disorders, which can be facilitated by the control of plasma glucose levels, insulin levels and / or insulin secretion, such as diabetes and associated with diabetes states. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, nutritional disorders, insulin resistance, obesity, and diabetes mellitus of any type, including type 1, type 2, and pregnancy diabetes.

EA200800548A 2005-08-11 2006-08-11 Hybrid polypeptides with selectable properties EA014647B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20166405A 2005-08-11 2005-08-11
US11/206,903 US8076288B2 (en) 2004-02-11 2005-08-17 Hybrid polypeptides having glucose lowering activity
US11/301,744 US7723471B2 (en) 2004-02-11 2005-12-12 Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
PCT/US2006/031724 WO2007022123A2 (en) 2005-08-11 2006-08-11 Hybrid polypeptides with selectable properties

Publications (2)

Publication Number Publication Date
EA200800548A1 true EA200800548A1 (en) 2008-08-29
EA014647B1 EA014647B1 (en) 2010-12-30

Family

ID=39662713

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800548A EA014647B1 (en) 2005-08-11 2006-08-11 Hybrid polypeptides with selectable properties

Country Status (7)

Country Link
JP (1) JP2009504681A (en)
KR (1) KR101399178B1 (en)
CN (1) CN101296942A (en)
EA (1) EA014647B1 (en)
IL (1) IL188937A0 (en)
MX (1) MX2008002028A (en)
ZA (1) ZA200801138B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120071401A1 (en) * 2009-04-10 2012-03-22 Amylin Pharamaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
MX2012005912A (en) * 2009-11-23 2012-10-05 Amylin Pharmaceuticals Inc Polypeptide conjugate.
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
NZ603169A (en) * 2010-04-27 2015-02-27 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
RU2552221C2 (en) * 2010-07-15 2015-06-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Method of treating obesity and accompanying metabolic disorders and medication for treating obesity and accompanying metabolic disorders
WO2012162547A2 (en) * 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates
TWI674270B (en) * 2012-12-11 2019-10-11 英商梅迪繆思有限公司 Glucagon and glp-1 co-agonists for the treatment of obesity
CA2957714A1 (en) * 2014-08-11 2016-02-18 Albany Medical College Myristoylated leptin-related peptides and uses thereof
KR101689803B1 (en) * 2015-11-17 2016-12-27 고려대학교 산학협력단 Composition for preventing or treating of diabetes or obesity containing Apelin-16
US11034745B2 (en) * 2016-01-04 2021-06-15 Adepthera Llc Superagonist polypeptide analogs of adrenomedullin and intermedin peptide hormones
JP6889432B2 (en) * 2016-04-28 2021-06-18 学校法人甲南学園 Resin-fixed peptide
AU2017318610B2 (en) * 2016-09-02 2021-12-09 The Board Of Trustees Of The University Of Illinois KIF13B-derived peptide and method of inhibiting Angiogenesis
CA3075867A1 (en) * 2017-09-13 2019-03-21 Gene Techno Science Co., Ltd. Anti-ramp2 antibody
MX2020011293A (en) * 2018-04-25 2020-11-13 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof.
US10875902B2 (en) 2018-04-25 2020-12-29 Janssen Pharmaceutica Nv Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
KR102116944B1 (en) * 2019-09-23 2020-05-29 주식회사 차메디텍 Novel peptide derivatives having melanin production inhibitory activity, pharmaceutically acceptable salts thereof, and composition for inhibiting melanin production comprising the same
CN117603364A (en) * 2022-09-30 2024-02-27 广西医科大学附属肿瘤医院 GLP-1/glucon/Y 2 Receptor triple agonists and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
WO1997026321A2 (en) * 1996-01-19 1997-07-24 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
AU1159897A (en) 1996-11-13 1998-06-03 University Of Cincinnati, The Analogs of peptide yy and uses thereof
EA004790B1 (en) * 1996-12-20 2004-08-26 Амген Инк. Ob fusion protein compositions and methods
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
WO2001051078A1 (en) * 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
CA2716959A1 (en) * 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
CA2455963C (en) * 2001-07-31 2017-07-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1, exendin-4, peptide analogs and uses thereof
US7192922B2 (en) * 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
EP1610811A4 (en) * 2002-12-17 2008-03-26 Amylin Pharmaceuticals Inc Prevention and treatment of cardiac arrhythmias
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US20070027073A1 (en) * 2003-04-08 2007-02-01 Menachem Rubinstein Long-acting derivatives of pyy agonists
CN1961000B (en) * 2004-02-11 2011-05-04 安米林药品公司 Hybrid polypeptides with selectable properties

Also Published As

Publication number Publication date
ZA200801138B (en) 2008-12-31
KR20080045185A (en) 2008-05-22
IL188937A0 (en) 2008-04-13
EA014647B1 (en) 2010-12-30
JP2009504681A (en) 2009-02-05
CN101296942A (en) 2008-10-29
MX2008002028A (en) 2008-03-27
KR101399178B1 (en) 2014-06-18

Similar Documents

Publication Publication Date Title
EA200800548A1 (en) HYBRID POLYPEPTIDES WITH SELECTED PROPERTIES
EA200701704A1 (en) ANALOGUES AND HYBRID POLYPEPTIDES OF GIP WITH ELECTABLE PROPERTIES
WO2007022123A3 (en) Hybrid polypeptides with selectable properties
WO2005077072A3 (en) Hybrid polypeptides with selectable properties
WO2008021560A3 (en) Dpp-iv resistant gip hybrid polypeptides with selectable properties
EP2330125A3 (en) Hybrid polypeptides with selectable properties
IL198922A0 (en) Chemical compounds and uses
WO2007007173A3 (en) Human anti-madcam antibodies
NL301089I2 (en) imlifidase
WO2006012577A3 (en) Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
EA200701471A1 (en) Substituted pyridinyl and pyrimidinyl derivatives, used as modulators of metabolic disease and treatment of disorders associated with it
WO2007109354A3 (en) Peptide-peptidase inhibitor conjugates and methods of using same
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
EA201000515A1 (en) АКТИВАТОРЫ ГЛЮКОКИНАЗЫ
WO2008077145A3 (en) Treatment of il-1-beta related diseases
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
WO2008106429A3 (en) Methods and compositions for the treatment of heart failure and other disorders
EA201300522A1 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS
EA200501132A1 (en) 1,2,3-triple substituted aryl and heteroaryl derivatives as modulators of metabolism and prophylaxis and treatment of disorders associated with it, such as diabetes and hyperglycemia
EA200700886A1 (en) CONNECTION OF TIADIAZOLE AND ITS APPLICATION
MX2007005590A (en) Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof.
EA200801716A1 (en) THIAZOLE COMPOUNDS AND THEIR APPLICATION
WO2007044591A3 (en) Vasoactive intestinal polypeptide pharmaceuticals
WO2010049678A3 (en) Treatment of energy utilization diseases
WO2007104789A3 (en) Amylin derivatives

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU